Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent activator of the cell death pathway and exerts tumoricidal activity in vivo with minimal toxicity. In order to investigate the therapeutic potential of TRAIL in B chronic lymphocytic leukemia (B-CLL) we have analyzed the expression of TRAIL receptors (TRAIL-Rs) in leukemic cells from B-CLL patients and their in vitro sensitivity to apoptosis induced by recombinant human TRAIL. We have found TRAIL-R1 and -R2 death receptor, and TRAIL-R3 and -R4 decoy receptor mRNA expression in most of the 57 B-CLL patients studied (R1 82%, R2 100%, R3 96% and R4 82%). TRAIL-R1 and R2 proteins were expressed on the surface and within the cells, whereas R3 and R4 decoy receptors were almost exclusively expressed in the cytoplasm. Despite TRAIL death receptor expression, B-CLL cells were relatively resistant to induction of apoptosis by recombinant human TRAIL (300 ng/ml). However, the susceptibility to TRAIL- 
Introduction
The TNF-related apoptosis-inducing ligand (TRAIL) is a type II membrane protein belonging to the TNF superfamily, capable of inducing apoptotic cell death in a variety of cell types. 1 Four distinct cell surface TRAIL receptors (TRAIL-Rs) have been identified, including TRAIL-R1/DR4, 2 TRAIL-R2/DR5/TRICK2, [3] [4] [5] TRAIL-R3/DcR1/TRID 3, [5] [6] [7] and TRAIL-R4/DcR2. 8, 9 TRAIL-R1 and -R2 contain a cytoplasmic death domain and signal for apoptotic cell death upon receptor cross-linking. In contrast, neither TRAIL-R3 nor -R4 contains a complete cytoplasmic death domain, which makes them unable to signal for cell death. TRAIL-R3 and TRAIL-R4 are believed to inhibit TRAIL-induced apoptosis either by acting as decoy receptors or by providing inhibitory signals such as activation of the transcription factor NF-B. 2, 5, 6, [8] [9] [10] Recombinant soluble forms of TRAIL are potent mediators of tumor cell apoptosis, but exert minimal cytotoxicity toward normal tissues. 11, 12 TRAIL and TRAIL-Rs are constitutively expressed in various normal human tissues, but the expression of the decoy receptors is minimal in malignant cells. 4, 5, 8 Therefore, it has been proposed that the expression of these receptors may determine the cell susceptibility to TRAILmediated apoptosis. 2, 5, 6, 8, 9 In addition to levels of expression and function of TRAIL-Rs, intracellular proteins that inhibit activation of caspases may be relevant for susceptibility to TRAIL-induced apoptosis. 10, 11, 13 Among them are viral FLICEinhibitory proteins (v-FLIP) and the human homologue called c-FLIP/Casper/I-FLICE/FLAME-1/CASH/MRIT/CLARP/Usurpin, which belong to the group of apoptosis inhibitory molecules. 14, 15 Several c-FLIP splice variants exist at the mRNA level, but only two endogenous forms, FLIP L and FLIP S , have been detected at the protein level. 15 FLIP L is structurally similar to procaspase-8, containing two death effector domains (DED) and a caspase-like domain, but lacks residues necessary for catalytic activity. FLIP S possesses two DEDs but no caspase-like domain. 15 Both FLIP variants are able to block procaspase-8 activation at the death-inducing signaling complex (DISC) and protect cells from death receptor-mediated apoptosis. [15] [16] [17] FLIP has been demonstrated to play a role in protection from apoptosis in a number of systems, especially those involving lymphoid cells. High expression of FLIP promotes tumor growth and facilitates immune escape of tumors. 18, 19 Constitutive, increased FLIP expression has also been correlated with resistance to TRAIL in primary and transformed cells. 11, 20, 21 In addition to FLIP, other intracellular antiapoptotic proteins, such as Bcl-2, Bcl-x L and IAP caspase inhibitors, may be important to determine tumor susceptibility to TRAIL-induced apoptosis. 22, 23 A high proportion of hematopoietic and non-hematopoietic tumor cell lines is sensitive to cytotoxic effects of TRAIL in vitro. 10 Systemic administration of TRAIL can reduce tumor growth and induce regression of tumor cell xenografts, without the toxic side-effects seen after administration of FasL or TNF.
12,24 B chronic lymphocytic leukemia (B-CLL) is characterized by the progressive accumulation of monoclonal CD5 + B lymphocytes in peripheral blood, bone marrow and lymphoid tissues. 25 The clinical course of B-CLL is highly variable, ranging from a long-term stable disease, requiring no therapy, to a rapidly progressing condition with significant morbidity and mortality. 26 It has been suggested that the accumulation of leukemic B cells results from uncharacterized defects in the apoptotic process, leading to a decreased rate of cell death. 27 B-CLL cells are relatively resistant to Fas-mediated apoptosis 28, 29 and show a variable sensitivity to drug-induced apoptosis. 30, 31 The overall Bcl-2/Bax ratio may determine chemosensitivity of B-CLL cells [30] [31] [32] and our previous studies support a regulatory role of Bcl-2/Bax in the survival of B-CLL cells. 33, 34 However, the mechanisms behind the resistance of B-CLL cells to apoptosis are largely still undefined. In the present study, we have investigated the sensitivity of B-CLL to TRAIL-mediated apoptosis. We found that, despite the expression of TRAIL death receptors, B-CLL cells are relatively resistant to TRAIL-induced apoptosis. However, inhibition of RNA synthesis by actinomycin D (Act D) increased the sensitivity of the leukemic cells to TRAIL, which correlated with a down-regulation of both long and short FLIP protein expression.
Materials and methods

Reagents
Actinomycin D and pronase E were purchased from Sigma Chemical (St Louis, MO, USA). Primers for TRAIL-R1, -2, -3, and -4 PCR amplification were synthesized by Eurogentec Bel (Seraing, Belgium). G3PDH primers were synthesized by Biosource Europe (Fleurus, Belgium). 3,3Ј-dihexyloxacarbocyanine iodide (DiOC 6 (3)) was from Molecular Probes (Eugene, OR, USA). Annexin-V-Fluos was from Roche Molecular Biochemicals (Mannheim, Germany). RNAzol B was from Biotecx Laboratories (Houston, TX, USA). Recombinant human TRAIL (LZ-TRAIL) was kindly supplied by Immunex (Seattle, WA, USA) as a leucine zipper fusion protein, which required no further cross-linking for maximal activity. Recombinant human soluble TRAIL (rhsTRAIL) from Alexis (Läufelfingen, Switzerland) was also used, in conjunction with an enhancer antibody (Alexis) to increase its activity.
Antibodies
Peroxidase-conjugated rabbit anti-goat Ig, fluorescein isothiocyanate (FITC)-conjugated F(abЈ) 2 fragment of rabbit antimouse Ig, FITC-F(abЈ) 2 fragment of rabbit anti-human IgM, phycoerythrin (PE)-conjugated anti-CD19, anti-CD3-PE, and anti-CD25-PE were from Dakopatts (Copenhagen, Denmark). Anti-CD5-PE and IgG1-FITC/IgG2a-PE simultest were from Becton Dickinson (Mountain View, CA, USA). Goat polyclonal antibody to human TRAIL-R2 and rat monoclonal antibody to human FLIP were from Alexis. Mouse monoclonal antibody to Bcl-2 (clone 124) was from Upstate Biotechnology (Lake Placid, NY, USA). Actin (1-19) goat polyclonal antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The mAbs against human TRAIL-R1 (IgG2a, huTRAILR1-M271), TRAIL-R2 (IgG1, huTRAILR2-M413), TRAIL-R3 (IgG1, huTRAILR3-M430) and TRAIL-R4 (IgG1, huTRAILR4-M445) were supplied by Immunex. 13 Purified mouse IgG2a and IgG1 isotype control immunoglobulins were from Pharmingen (San Diego, CA, USA).
Patients
Fifty-seven B-CLL patients, 24 women and 33 men, with a mean age of 73 years (range 54 to 89 years) were included in this study. All patients had a monoclonal B cell fraction ( or light chains) and were staged according to Rai. 35 Patients were considered to have progressive disease, according to a modification of the criteria by the NCI Committee, 36 if there was progression during the preceding 3 months in diseaserelated anemia (Hb Ͻ100 g/l), in thrombocytopenia (platelet count Ͻ100 × 10 9 /1) and/or in spleen/liver/lymph node size (evaluated by both clinical examination and computer tomography of the abdomen) and/or in more than a doubling of the blood lymphocyte counts and/or appearance of constitutional symptoms. When these criteria were not fulfilled, B-CLL patients were defined as having non-progressive disease.
Leukemia
Cell lines and cell separation
The Jurkat T cell line, and the K562 cell line were purchased from American Tissue Culture Collection (Manassas, VA, USA). Murine B lymphoma A20 cell lines transfected with human FLIP L , human FLIP S or with an empty vector were kindly provided by Prof A Grandien (Stockholm University, Sweden). Cell lines were cultured in RPMI 1640 medium supplemented with 2 mm glutamine, 100 U/ml penicillin, 100 g/ml streptomycin and 10% FCS. Murine B lymphoma A20 cell lines were cultured in the presence of 50 m 2-mercaptoethanol. Leukemic B cells and unfractionated normal B cells were isolated from heparinized blood of B-CLL patients after informed consent and from tonsil tissue, respectively. Lymphocytes were obtained after carbonyl iron treatment and Lymphoprep centrifugation, and T cells depleted by rosetting with sheep erythrocytes. Isolated cells were kept frozen in aliquots. Isolated non-rosetting, leukemic B cells contained less than 0.2% CD3 + cells as estimated by flow cytometry.
Cell phenotype
Isolated cells from all B-CLL patients were phenotyped by immunofluorescence and flow cytometry. Cells (1 × 10 6 ) were incubated for 30 min at 4°C with anti-CD5-PE, anti-CD19-PE, anti-CD25-PE, anti-CD3-PE, or FITC-F(abЈ) 2 anti-human IgM. FITC/PE-conjugated simultest was used as control. All samples were analyzed in a Becton Dickinson FACScan system equipped with an argon laser, using 10 000 cells for each determination. B-CLL cells were positively stained as follows: 95 ± 5.4% CD5, 97.8 ± 3% CD19, 59.2 ± 34% CD25 and 59 ± 32% IgM.
Flow cytometry analysis for TRAIL-R
Cells (1 × 10 6 ) were incubated for 30 min at 4°C with appropriate concentrations of TRAIL-R mAbs in 100 l of PBS with 1% bovine serum albumin (BSA). Cells were washed twice with PBS plus 1% BSA and then incubated with FITC-F(abЈ) 2 fragment of rabbit anti-mouse Ig for 30 min at 4°C. Intracellular staining was done as described elsewhere. 37 Briefly, cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.1% saponin in PBS with 0.1% BSA and stained for 30 min at 4°C with TRAIL-R mAbs. The cells were washed and stained with FITC-F(abЈ) 2 fragment of rabbit anti-mouse Ig for 30 min at 4°C. Cells incubated with irrelevant mouse IgG1 or IgG2a Ig were used as negative controls. After washing, the cells were analyzed by flow cytometry. Forward and side scatter gates were set to exclude dead cells.
In order to distinguish between membrane bound and intracellular TRAIL receptors, we performed TRAIL-R1 staining in both permeabilized and non-permeabilized B-CLL cells, as described above, following treatment with pronase enzyme (8 mg/ml) for 2 h at 8°C. Pronase treatment completely eliminated TRAIL-R1 expression on the cell surface in non-permeabilized cells, as compared to non-treated cells. However, TRAIL-R1 was detected in both pronase-treated and nontreated cells, fixed and permeabilized cells (data not shown). Thus, the procedure discriminated between intracellular and membrane expression.
Leukemia
Apoptosis
Tumor sensitivity to TRAIL was assayed by incubating Jurkat cells or isolated B cells in 96-well plates (0.4 × 10 6 cells/well) with LZ-TRAIL (1-300 ng/ml) or with rhsTRAIL plus the enhancer (2 g/ml) for 24 and 48 h. In some experiments nontoxic concentrations of Act D were added to the culture medium immediately before addition of TRAIL. Apoptosis was determined by annexin-V staining. Cells were washed with PBS and incubated for 10 min in 100 l of binding buffer (10 mm Hepes/NaOH, pH 7.4, 140 mm NaCl, 5 mm CaCl 2 ) containing annexin V-Fluos solution and 2 g/ml propidium iodide. Without washing, 300 l of binding buffer were added and cells were analyzed with FACScan. Apoptosis was also determined by evaluating loss in the mitochondrial transmembrane potential (⌬⌿ m ) with DiOC 6 (3) staining. 38 Cells were incubated with DiOC 6 (3) (40 nm in PBS) for 30 min at 37°C, washed with cold PBS and directly analyzed with cytofluorometer.
Western blot analysis
Cells were lysed at 4°C in lysis buffer (5 m NaCl, 1 m Tris pH 8, 0.5% Triton X-100, 2 mm PMSF and 10 g/ml leupeptin for TRAIL-R2 blots and 1.2% NP-40, 150 mm NaCl, 25 mm Hepes, 0.5% deoxycholat, 5 mm NaF, 2 mm PMSF and 10 g/ml leupeptin for FLIP blots), followed by high-speed centrifugation to remove cellular debris. Protein concentration was determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of protein were separated on SDS-PAGE and electroblotted on to nitrocellulose (Bio-Rad) or PVDF (Amersham Pharmacia Biotech, Piscataway, NJ, USA) membranes for probing against TRAIL-R2 and FLIP, respectively. Ponceau S (Sigma) staining was used to control equal protein loading. After blocking for 1 h in 5% nonfat dry milk in PBS-Tween-20 (0.05%, v/v) immunodetection of TRAIL-R2 or FLIP was done using goat anti-human TRAIL-R2 antibody (1:500) or rat anti-human FLIP monoclonal antibody (1:1000), followed by horseradish peroxidase-conjugated rabbit anti-goat Ig (1:1000) or rabbit anti-rat Ig (1:1000). Anti-actin goat polyclonal antibody was used to control protein loading. The membranes used for detection of FLIP were sequentially probed with anti-actin antibody and mouse antiBcl-2 followed by peroxidase-conjugated anti-goat and antimouse antibodies, respectively, stripping between each detection with 2% SDS in PBS containing 2 m 2-mercaptoethanol. Blots were washed and developed by chemiluminescence according to the manufacturer's protocol (ECL; Amersham Pharmacia Biotech). For quantification, the blots were subjected to Multi-Imager analysis using the Image Quant software (Molecular Dynamics, Sunnyvale, CA, USA).
RT-PCR for human TRAIL receptors
Total RNA was extracted from 10 × 10 6 isolated B cells with RNAzol B and quantified by spectrophotometry. Three micrograms of total RNA were denatured and reverse transcribed using random hexanucleotides. Thereafter, 1 l (75 ng) of cDNA was amplified in a 20 l PCR reaction mixture. The PCR was performed using the following sense and antisense primers: G3PDH (983 bp), 5ЈTGAAGGTCGGAG TCAACGGATTTGGT3Ј and 5ЈCATGTGGGCCATGAGGT CCACCAC3Ј; TRAIL-R1 (506 bp), 5ЈCTGAGCAACGCAGAC TCGCTGTCCAC3Ј and 5ЈTCCAAGGACACGGCAGAGCCT GTGCCAT3Ј; TRAIL-R2 (512 bp), 5ЈGCCTCATGGACAATGA GATAAAGGTGGCT3Ј and 5ЈCCAAATCTCAAAGTACGCA CAAACGG3Ј; TRAIL-R3 (612 bp), 5ЈGAAGAATTTGGT GCCAATGCCACTG3Ј and 5ЈCTCTTGGACTTGGCTGGGA GATGTG3Ј; TRAIL-R4 (464 bp), 5ЈCTTTTCCGGCGGCGTTC ATGTCCTTC3Ј and 5ЈGTTTCTTCCAGGCTGCTTCCCTTT GTAG3Ј. PCR was performed for 38 cycles, 1 min 94°C, 1 min 60°C and 1 min 72°C for G3PDH; 30 cycles, 1 min at 94°C, 1 min at 55°C and 1 min at 72°C for TRAIL-R1 and -R2 and 39 cycles, 1 min at 95°C, 1 min 57°C and 1 min 72°C for TRAIL-R3. TRAIL-R4 cycle conditions were 95°C for 4 min 15 s, followed by 30 cycles of 95°C for 45 s, 60°C for 45 s, and 72°C for 45 s. The samples were then resolved on a 2% agarose gel with 1 g/ml of ethidium bromide and photographed. Densitometric analysis was performed using Image Quant software (Molecular Dynamics) and mRNA levels were normalized to G3PDH mRNA expression.
Statistical analysis
Estimation of statistical differences was done with the Wilcoxon signed rank test for paired samples. Pearson's coefficient of correlation was used to analyze correlations between independent observations and two-tailed statistical significances were determined.
Results
TRAIL receptor mRNA expression in B-CLL cells
mRNA expression of TRAIL-R1 and -R2 death receptors, and TRAIL-R3 and -R4 decoy receptors was analyzed in 57 B-CLL patients (28 progressive and 29 non-progressive) by RT-PCR, using oligonucleotide primers derived from unique regions in each TRAIL receptor sequence. 11 Upon this analysis the following mRNA expression patterns were observed: 82% of the patients (47/57) expressed TRAIL-R1, 100% expressed TRAIL-R2, 96% (55/57) expressed TRAIL-R3 and 82% (47/57) expressed TRAIL-R4. There was no correlation between overall TRAIL-R1 or -R4 mRNA expression and progression of the disease. However, semiquantitative analysis showed significantly higher levels of TRAIL-R1 and −R4 mRNA in progressive patients in comparison to non-progressive B-CLL patients (mean; s.d.: 0.95; 0.9 vs 0.51; 0.6 for TRAIL-R1; 1.02; 0.8 vs 0.54; 0.6 for TRAIL-R4, P Ͻ 0.03; Figure 1 ). Significant differences were also observed in mRNA levels of TRAIL-R1 and -R4 between patients in stage 0 and stage III (mean; s.d.: 0.4; 0.7, n = 15 vs 1.16; 1.1, n = 8 for TRAIL-R1, P Ͻ 0.01; 0.6; 0.6, n = 15 vs 1.2; 0.6, n = 8 for TRAIL-R4, P Ͻ 0.03).
B-CLL cells express TRAIL receptor proteins but are resistant to TRAIL-induced apoptosis
Signals transduced through either TRAIL-R1 or TRAIL-R2 are necessary and sufficient to induce TRAIL-mediated cell death. 13 It has been postulated that TRAIL interaction with the decoy receptors, TRAIL-R3 and -R4 results in inhibition of TRAIL-induced cell death. 5 We first examined TRAIL receptor protein expression by flow cytometry in permeabilized and non-permeabilized B-CLL cells. Representative flow cytometry histograms from four patients are shown in Figure 2 and a summary from 15 B-CLL patients is shown in Table 1 . All the B-CLL cells expressed TRAIL-R1 and -R2 on the cell surface and most of them also within their cytoplasm, which was correlated with mRNA expression. Cells from 10 B-CLL patients previously studied by flow cytometry and from an additional three B-CLL patients (L-244, L-243 and L-249) were also positive for TRAIL-R2 protein by Western blot analysis (Figure 3) . Results on decoy receptor protein expression by flow cytometry showed low or no expression of TRAIL-R4 in both permeabilized and non-permeabilized B-CLL cells ( Figure 2 and Table 1 ). B-CLL cells were also negative or weakly positive for TRAIL-R3 protein on the cell surface, but TRAIL-R3 was detected at high levels in permeabilized cells (Figure 2 and Table 1 ).
We next analyzed the susceptibility of B-CLL cells to TRAILinduced apoptosis by using annexin-V staining in B-CLL cells treated for 24 and 48 h with a range of concentrations (1-300 ng/ml) of LZ-TRAIL. TRAIL-sensitive Jurkat cells 39 were used as positive controls. B-CLL cells were found to be relatively resistant to apoptosis even at 300 ng/ml of LZ-TRAIL (Table 1, Figure 4 and data not shown), which was chosen for further experiments. Only 3/8 patients (L-252, L-233 and L-263) showed more than 25% increase in percentage of apoptotic cells after TRAIL treatment, as compared to their controls (Table 1 and Figure 4) . Treatment of B-CLL cells with rhsTRAIL added with an enhancer to cross-link TRAIL, yielded similar results (not shown). Apoptosis was also analyzed by DiOC 6 (3) staining, which produced similar results (not shown). Regression analyses of the data from the patients in Table 1 showed a correlation between the surface protein expression of TRAIL-R2 and TRAIL-induced apoptosis (r = 0.56, P = 0.043; r = 0.64, P = 0.023, for 24 and 48 h, respectively).
Leukemia
Our results demonstrate that B-CLL resistance to TRAILinduced apoptosis is not due to absence of TRAIL death receptors.
Actinomycin D increases B-CLL cell sensitivity to TRAIL-induced apoptosis
Sub-toxic concentrations of the RNA synthesis inhibitor Act D are known to increase the level of sensitivity of some cell types to Fas-, TNF␣-or TRAIL-mediated cytotoxicity.
11,40
Therefore, we examined the effect of Act D on TRAILmediated apoptosis in B-CLL cells by treating them with a non-toxic concentration of Act D, followed by 300 ng/ml of LZ-TRAIL and measuring apoptosis by annexin-V staining after 24 and 48 h. A significant increase in TRAIL-induced apoptosis was observed after 24 h (P Ͻ 0.006, Figure 4a) , and more evidently after 48 h (P Ͻ 0.001, Figure 4b 
Act D down-regulates the expression of FLIP L and FLIP S , but not TRAIL-Rs or Bcl-2 in B-CLL cells
To investigate the mechanism of sensitization of B-CLL cells to TRAIL by Act D, we examined the effect of Act D on the expression of TRAIL-Rs, and the anti-apoptotic proteins, FLIP and Bcl-2. Surface and intracellular TRAIL-R expression was examined by FACS analysis. Surprisingly, the expression of TRAIL-R1 and TRAIL-R2 was increased after 18 h culture of the cells in medium alone, as compared to constitutive basal expression, and TRAIL-R2 was further slightly increased after 18 h of Act D treatment. However, these changes were not correlated with the Act D-induced gain in the susceptibility of B-CLL cells to TRAIL-mediated apoptosis (not shown). The expression of TRAIL-R3 and -R4 was not affected by cell culture or by Act D treatment (not shown). Thus, modulation of TRAIL-Rs expression does not seem to be one mechanism associated with the Act D-induced increase in the B-CLL susceptibility to TRAIL-mediated apoptosis.
FLIP and Bcl-2 proteins have been reported to confer resistance to TRAIL-mediated apoptosis in some cell types. 
Discussion
We have studied TRAIL-mediated cell death in B-CLL and demonstrated that although B-CLL cells express TRAIL death receptors, they are relatively resistant to TRAIL-induced apoptosis. We also showed that B-CLL cells become more susceptible to TRAIL after Act D treatment. Previous studies suggested that the sensitivity to TRAIL-induced apoptosis is regulated by the presence or absence of the TRAIL death and decoy receptors. 5, 10 We studied the TRAIL-R mRNA expression by RT-PCR in 57 B-CLL patients. B-CLL cells from all the patients were positive for TRAIL-R2 mRNA and most of them were also positive for TRAIL-R1 mRNA. TRAIL-R1 and TRAIL-R2 protein were detected both on the cell surface and in the cytoplasm. In contrast, although B-CLL cells expressed TRAIL-R3 and -R4 mRNA, they were negative or weakly positive for cell surface expression. However, they expressed significant levels of intracellular TRAIL-R3. Zhang et al 37 reported similar results on melanoma cell lines. Their confocal microscopy studies indicated that TRAIL-R2 is clustered in organelles, similar to the Golgi apparatus, whereas TRAIL-R3 and -R4 are located in the nucleus. 37, 43 Our results show that despite the expression of TRAIL-R1 and -R2 on B-CLL cells, they were relatively resistant to in vitro induction of apoptosis by recombinant human TRAIL. The fact that Act D treatment sensitizes B-CLL cells to TRAIL-mediated apoptosis, also indicates that the relative resistance of B-CLL to TRAIL is not due to functional defects of the death receptors.
Some of the B-CLL patients were more sensitive to TRAIL and they had higher levels of TRAIL-R2 protein on the cell surface. TRAIL-R1 and TRAIL-R2 were spontaneously up-regulated in cells cultured in medium alone and TRAIL-R2 was also up-regulated on the surface of Act D pretreated cells. However, there was no correlation between the protein expression level of TRAIL-death receptors and decoy receptors, and the B-CLL sensitivity to TRAIL. All together, these results suggest that modulation of TRAIL-Rs expression is not the mechanism by which Act D sensitizes B-CLL cells to TRAIL, and that other factors may determine the TRAIL resistance of B-CLL.
Other authors have also found no correlation between levels of decoy receptors and resistance to TRAIL in various tumors tissues and cell lines. 5, 11, [44] [45] [46] Conflicting reports have not been able to clarify which levels of TRAIL-R3 or -R4, or which ratio between decoy receptors and death receptors is required for an inhibitory effect on TRAIL-induced apoptosis. 2, 5, 6, 8, 9 Furthermore, it has been suggested that the ability of TRAIL-R3 or -R4 to inhibit TRAIL-mediated killing might result from signaling activities other than apoptosis, associated with these receptors.
47 TRAIL-R4 is capable of NF-B activation 8 and TRAIL-R3 may signal via the GPI (glycosylphosphatidylinositol) anchors. 47 Thus, since TRAIL-R3 receptors were found within B-CLL cells, their role in regulating B-CLL sensitivity to TRAIL-induced apoptosis requires further investigation.
In agreement with our results, previous reports have also shown the increase in the sensitivity of tumor cells to TRAIL by protein or nucleic acid synthesis inhibitors. 11, 40, 48 The fact that Act D can sensitize some tumors to TRAIL suggests the presence of one or more short-lived anti-apoptotic proteins, which are able to block TRAIL-induced apoptosis signaling. Although the signaling pathway used by TRAIL to induce apoptosis has yet to be fully elucidated, it has already been shown that FADD and caspase-8 are components of the TRAIL-DISC. 1, 49, 50 FLIP possesses DEDs through which it interrupts FADD and caspase-8 binding, preventing DISC formation and apoptosis. 15 Since ligand-dependent association of the TRAIL-R2 death domain and FLIP have been found, 51 FLIP is a prime candidate for intracellular regulation of caspase activation by TRAIL. Accordingly, FLIP expression has been correlated with TRAIL resistance in tumor and normal cells lines. 11, 15, 20, 21 In addition, Act D treatment of melanoma 11 and other cell types 52 sensitizes them to TRAIL by downregulation FLIP.
Here, we have shown that Act D decreased FLIP L expression in B-CLL cells at the same concentration and time that induced a gain in susceptibility to TRAIL-induced apoptosis. Act D treatment also induced a down-regulation of FLIP S , which occurred some hours before the increase in TRAILmediated apoptosis was observed. It has been shown that both FLIP forms coexist in the same DISC upon Fas triggering, and both molecules inhibit procaspase-8 activation and apoptosis upon overexpression. 16, 17 Some differences have been described regarding the molecular mechanism of action of the two FLIP proteins and in their capacity to activate various signaling pathways. FLIP S completely inhibits cleavage of procaspase-8, and FLIP L allows partial but not complete proteolytical processing of caspase-8. 16 FLIP L preferentially activated NFLeukemia B and FLIP S more strongly activated Erk. 53 Although we found FLIP L and FLIP S down-regulated by Act D, the precise contribution of these two forms of FLIP in the sensitivity to TRAIL-mediated apoptosis in B-CLL requires further investigation. Surprisingly, FLIP L and FLIP S were spontaneously upregulated in cells cultured in medium alone. Although FLIP L levels were down-regulated by Act D treatment, they were not lower than the constitutive expression levels, but still the cells were sensitized to TRAIL. These findings indicate that the availability, relative local concentrations of FADD, caspase-8, FLIP L , FLIP S and TRAIL-Rs as well as their affinities for each other are critical parameters that need to be studied to define the role of FLIP in TRAIL-mediated apoptosis in B-CLL.
In conclusion, here we present evidence that suggests that FLIP may be an important determinant in TRAIL resistance of B-CLL. First, B-CLL cells have a high constitutive expression of FLIP. Second, in vitro treatment of B-CLL cells with the RNA synthesis inhibitor, Act D, induces down-regulation of FLIP L and FLIP S , which is correlated with a gain in sensitivity to TRAIL-induced apoptosis. Kitada et al 54 reported a reduced spontaneous, drug-and Fas-induced apoptosis in CD40L-treated B-CLL cells with up-regulated FLIP L and FLIP S , which supports the role of FLIP in B-CLL apoptosis. Ongoing experiments in our laboratory, examining the effect of antisense oligonucleotide to FLIP on the B-CLL sensitivity to TRAIL, would confirm this hypothesis. We do not exclude the possibility that anti-apoptotic molecules other than FLIP, such as Bcl-x L and IAP family members might also contribute to the resistance of B-CLL to TRAIL. Our results could have important implications for effective combined treatment regimens that enhance the apoptotic response of B-CLL to TRAIL. Further studies of the mechanisms involved in TRAIL-mediated cytotoxicity are required to assess the potential use of TRAIL as an anti-cancer agent in vivo.
